Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 284

1.

Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.

Nathan SD, du Bois RM, Albera C, Bradford WZ, Costabel U, Kartashov A, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE Jr.

Respir Med. 2015 Jul;109(7):914-22. doi: 10.1016/j.rmed.2015.04.008. Epub 2015 Apr 24.

2.

Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.

Lederer DJ, Bradford WZ, Fagan EA, Glaspole I, Glassberg MK, Glasscock KF, Kardatzke D, King TE Jr, Lancaster LH, Nathan SD, Pereira CA, Sahn SA, Swigris JJ, Noble PW.

Chest. 2015 Jul 1;148(1):196-201. doi: 10.1378/chest.14-2817.

PMID:
25856121
3.

Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.

Costabel U, Albera C, Bradford WZ, Hormel P, King TE Jr, Noble PW, Sahn SA, Valeyre D, Du Bois RM.

Sarcoidosis Vasc Diffuse Lung Dis. 2014 Oct 20;31(3):198-205.

PMID:
25363219
4.

Characteristics of patients with yellow nail syndrome and pleural effusion.

Valdés L, Huggins JT, Gude F, Ferreiro L, Alvarez-Dobaño JM, Golpe A, Toubes ME, González-Barcala FJ, José ES, Sahn SA.

Respirology. 2014 Oct;19(7):985-92. doi: 10.1111/resp.12357. Epub 2014 Aug 14. Review.

5.

Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.

Valeyre D, Albera C, Bradford WZ, Costabel U, King TE Jr, Leff JA, Noble PW, Sahn SA, du Bois RM.

Respirology. 2014 Jul;19(5):740-7. doi: 10.1111/resp.12297. Epub 2014 May 18.

6.

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group.

N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18. Erratum in: N Engl J Med. 2014 Sep 18;371(12):1172.

7.

All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.

King TE Jr, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, Nathan SD, Sahn SA, Valeyre D, Noble PW.

Am J Respir Crit Care Med. 2014 Apr 1;189(7):825-31. doi: 10.1164/rccm.201311-1951OC.

PMID:
24476390
8.

6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.

du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE Jr.

Eur Respir J. 2014 May;43(5):1421-9. doi: 10.1183/09031936.00131813. Epub 2013 Dec 5.

PMID:
24311766
9.

Improving the predictive accuracy of identifying exudative effusions.

Kummerfeldt CE, Chiuzan CC, Huggins JT, DiVietro ML, Nestor JE, Sahn SA, Doelken P.

Chest. 2014 Mar 1;145(3):586-92. doi: 10.1378/chest.13-1142.

PMID:
24008773
10.

Pulmonary capillaritis in a patient with moderately positive anti-PL-12 antibodies.

Kummerfeldt CE, Huggins JT, Riemer EC, Ravenel JG, Whelan TP, Sahn SA.

Int J Rheum Dis. 2013 Apr;16(2):233-4. doi: 10.1111/1756-185X.12058. Epub 2013 Apr 4. No abstract available.

PMID:
23773650
11.

Can tuberculous pleural effusions be diagnosed by pleural fluid analysis alone?

Sahn SA, Huggins JT, San José ME, Álvarez-Dobaño JM, Valdés L.

Int J Tuberc Lung Dis. 2013 Jun;17(6):787-93. doi: 10.5588/ijtld.12.0892.

PMID:
23676163
12.

Effects of coexisting pneumonia and end-stage renal disease on pleural fluid analysis in patients with hydrostatic pleural effusion.

Doelken P, Huggins JT, Goldblatt M, Nietert P, Sahn SA.

Chest. 2013 Jun;143(6):1709-16. doi: 10.1378/chest.12-2221.

13.

More pearls afoot.

Heffner JE, Sahn SA, Harding SM.

Chest. 2013 Jan;143(1):5-7. doi: 10.1378/chest.12-1985. No abstract available.

PMID:
23276836
14.

Parasitic diseases of the pleura.

Lal C, Huggins JT, Sahn SA.

Am J Med Sci. 2013 May;345(5):385-9. doi: 10.1097/MAJ.0b013e318266e984. Review.

PMID:
22990049
15.

Unusual bacterial infections and the pleura.

Kummerfeldt CE, Huggins JT, Sahn SA.

Open Respir Med J. 2012;6:75-81. doi: 10.2174/1874306401206010075. Epub 2012 Sep 6.

16.

Getting the most from pleural fluid analysis.

Sahn SA.

Respirology. 2012 Feb;17(2):270-7. doi: 10.1111/j.1440-1843.2011.02100.x. Review.

PMID:
22059482
17.

Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.

du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, King TE Jr, Lancaster L, Noble PW, Sahn SA, Thomeer M, Valeyre D, Wells AU.

Am J Respir Crit Care Med. 2011 Dec 15;184(12):1382-9. doi: 10.1164/rccm.201105-0840OC. Epub 2011 Sep 22.

PMID:
21940789
18.

Intrapleural therapy.

Huggins JT, Doelken P, Sahn SA.

Respirology. 2011 Aug;16(6):891-9. doi: 10.1111/j.1440-1843.2011.02011.x. Review.

PMID:
21672085
19.

Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.

du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Raghu G, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE Jr.

Am J Respir Crit Care Med. 2011 Aug 15;184(4):459-66. doi: 10.1164/rccm.201011-1790OC.

PMID:
21616999
20.

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM; CAPACITY Study Group.

Lancet. 2011 May 21;377(9779):1760-9. doi: 10.1016/S0140-6736(11)60405-4. Epub 2011 May 13.

PMID:
21571362
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk